Chinese CAR-T cell clinical and therapeutic have entered a period of rapid growth!
**Chinese CAR-T cell clinical and therapeutic have entered a period of rapid growth!**
Chinese CAR-T
According to the American clinical trial database Clinicaltrials, as of November 10, 2023, China has taken the lead in CAR-T cell therapy clinical research with a total of 655 studies, marking the country’s first foray into the international forefront of a new drug development field. Among them, Legend Biotech’s SicajioLunsei and Koji Pharmaceutical’s Claudin18.2 CAR-T have both achieved global leadership. Additionally, several companies are also advancing next-generation CAR-T and allogeneic CAR-T technologies, showing promising initial data and potential for global market success.
CAR-T therapy
In terms of pricing, all three Chinese CAR-T therapies cost less than 1.3 million RMB (approximately 180,000 USD), only one-third of Novartis’s Kymriah. Specifically, JW Therapeutics’ Beinoda (Relmacabtagene autoleucel) is priced at 1.29 million RMB, FOSUNKITE’s Yikaida (Yescarta) is priced at 1.2 million RMB, and IASO’s Fukesu (Equecabtagene ciloleucel) is priced at 1.166 million RMB. Furthermore, Juventas, a domestic Chinese CAR-T product developed by Hegen Biotech, has set a new milestone in the pricing of Chinese CAR-T therapy, priced at 999,000 RMB per dose (less than 140,000 USD).
The year 2021 marked the beginning of cellular immunotherapy in China, with CAR-T therapy leading the way as one of the future development directions. CAR-T therapy primarily involves modifying T cells to recognize specific targets on tumor cells. Theoretically, there could be countless CAR-T therapies targeting different targets, which means endless possibilities.
We hope that in the near future, with the efforts of medical researchers both domestically and internationally, we can reduce the side effects of cell therapy, lower prices, and break through the bottleneck of solid tumors, benefiting more and more late-stage cancer patients!